Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

View

000402832700025.pdf (871.6Kb)

Identifiers

URI: http://hdl.handle.net/20.500.13003/10944

DOI: 10.1038/leu.2017.58

ISSN: 0887-6924

eISSN: 1476-5551

WOS ID: 000402832700025

Scopus EID: 2-s2.0-85014659967

PMID: 28210002

Embase PUI: L614736600

Metrics

10.1038/leu.2017.58

 

 

Share

Export

External links

Statistics

Item usage statistics

Metadata

Show Dublin Core item record

Author

Martinez-Lopez, J.; Sanchez-Vega, B.; Barrio, S.; Cuenca, I.; Ruiz-Heredia, Y.; Alonso, R.; Rapado, I.; Marin, C.; Cedena, M-T; Paiva, B.; Puig, N.; Mateos, M-V; Ayala, R.; Hernandez, M-T; Jimenez, C.; Rosinol, L.; Martinez, R.; Teruel, A-I; Gutierrez, N.; Martin-Ramos, M-L; Oriol, A.; Bargay Lleonart, Joan ; Blade, J.; San-Miguel, J.; Garcia-Sanz, R.; Lahuerta, J-J

Publication date

2017-06

Document type

letter to the editor

Citation

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.

Publisher version

https://dx.doi.org/10.1038/leu.2017.58

MeSH

Aged
Male
Monitoring, Physiologic
Multiple Myeloma
Neoplasm, Residual
Female
High-Throughput Nucleotide Sequencing
Humans
Survival Analysis
Antineoplastic Combined Chemotherapy Protocols

DeCS

Humanos
Protocolos de Quimioterapia Combinada Antineoplásica
Análisis de Supervivencia
Anciano
Monitoreo Fisiológico
Mieloma Múltiple
Femenino
Secuenciación de Nucleótidos de Alto Rendimiento
Neoplasia Residual
Masculino

This item appears in following Docusalut collections

Instituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica
Hospital Universitario Son Llàtzer - HUSLL > Comunicación científica